


High Patient Engagement with the ID-Cap™ System on 98.0% of Use-Days in a Clinical Study During the COVID-19 Pandemic

COVID-19 caused many interruptions in clinical trials. After a brief pause in external clinical research, clinical studies involving use of the FDA-cleared ID-Cap System from etectRx resumed in July of 2020. etectRx sought to understand if patients were engaged with our digital pill system when used to track and report their medication-taking in a clinical study conducted during the COVID-19 pandemic.

Within an ongoing clinical study, participant engagement with the ingestible ID-Capsule, wearable Reader and Patient App on a smartphone was high overall across all patients enrolled from July 2020 through February 2021 (median >100 days of use per participant). In this clinical study, medication adherence was tracked using the ID-Cap System for therapeutic agents required to be taken daily for treatment success.

etectRx evaluated patient engagement with the ID-Cap System on 1,270 use-days during these eight months of use in this study population. Participants successfully used the system to record ingestion events on 98.0% of use-days (1,245 days with recorded events/1,270 use-days). The patients utilized and wore the ID-Cap Reader as instructed on over 95.4% of use-days, enabling remote tracking and reliable reporting of their medication adherence throughout the study. etectRx did not observe any decline in patient engagement with the system over time. On only 33 days of the 1,270 monitored use-days (2.6%), an ingestion event was self-reported by the study participant via the Patient App rather than being recorded via the wearable Reader.

ID-Cap System Use Metrics in A Clinical Study Conducted During the COVID-19 Pandemic



These results are exciting, and we expect increased ease of use, convenience and patient acceptability in future readers that are currently in our development pipeline. The ID-Cap System has proven results of high patient engagement and successful implementation when used in clinical trials.

Acknowledgment: etectRx was granted special permission from the principal investigator to share this data on participant engagement with the ID-Cap System during the COVID-19 pandemic.

Source: Data on file at etectRx, Inc. This study is ongoing. Full study results forthcoming.